Anidulafungin

What it is used for

ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections: Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) Esophageal candidiasis in adults Limitations of use ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida or in sufficient numbers of neutropenic patients.

The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ( 1.3, 5.3, 8.4 ) ERAXIS is associated with high relapse rates in esophageal candidiasis. ( 1.3, 14.2 ) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis in adults and pediatric patients 1 month of age and older.

Esophageal Candidiasis ERAXIS is indicated for the treatment of esophageal candidiasis in adults. Limitations of Use ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida, and has not been studied in sufficient numbers of neutropenic patients to determine efficacy in this group.

The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ERAXIS is associated with high relapse rates in esophageal candidiasis. Usage Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s).

Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.

Side effects, and when to stop

The following most serious adverse reactions are described elsewhere in other labeling sections:

• Hepatic Adverse Reactions
• Anaphylactic and Hypersensitivity Reactions

Who should not take it

ERAXIS is contraindicated in:

• Patients with known hypersensitivity to anidulafungin, any component of ERAXIS, or other echinocandins
• Patients with known or suspected Hereditary Fructose Intolerance (HFI)